UroGen Pharma (STU:UR8) 3-Month Share Buyback Ratio : -0.10% (As of Dec. 2024 )

View and export this data going back to 2018. Start your Free Trial

What is UroGen Pharma 3-Month Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. UroGen Pharma's current 3-Month Share Buyback Ratio was -0.10%.

Competitive Comparison of UroGen Pharma's 3-Month Share Buyback Ratio

For the Biotechnology subindustry, UroGen Pharma's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

UroGen Pharma's 3-Month Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's 3-Month Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

UroGen Pharma 3-Month Share Buyback Ratio Calculation

UroGen Pharma's 3-Month Share Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

3-Month Share Buyback Ratio	=	(Shares Outstanding (EOP) (Sep. 2024 )	-	Shares Outstanding (EOP) (Dec. 2024 ))	/	Shares Outstanding (EOP) (Sep. 2024 )
	=	(42.191	-	42.232)	/	42.191
	=	-0.10%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UroGen Pharma (STU:UR8) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

UroGen Pharma 3-Month Share Buyback Ratio Related Terms

UroGen Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UroGen Pharma Ltd (STU:UR8) » Definitions » 3-Month Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

URGN:USA 0XOD:UK

Address

400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540

Website

https://www.urogen.com

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

UroGen Pharma Headlines

No Headlines